{'fraction_non_alphanumeric': 0.04337899543378995, 'fraction_numerical': 0.0289193302891933, 'mean_word_length': 4.9772727272727275, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells].

OBJECTIVE
To investigate the anti-proliferation and pro-apoptotic effects of different sequence schemes of zoledronic acid plus paclitaxel upon the hormone-refractory prostate cancer cell lines DU145 in vitro so as to provide the potentially optimal sequence scheme of these two drugs.


METHODS
MTT assay and Annexin V-FITC/PI double-staining flow cytometry were employed to observe the effects of zoledronic acid plus paclitaxel upon anti-proliferation and apoptosis induction respectively.


RESULTS
Inhibition of cellular growth by (44.17+/-5.81)% was observed under the treatment of paclitaxel and then zoledronic acid. Such a regimen was superior to the treatment of zoledronic acid and then paclitaxel or zoledronic acid (32.81+/-5.13)% plus paclitaxel (36.43+/-5.75)%. In comparisons with other groups, the treatment of paclitaxel and then zoledronic acid induced the maximal apoptosis (14.96%) and necrosis (14.37%) as shown by Annexin V-FITC/PI double-staining flow cytometry.


CONCLUSION
For the maximal anti-proliferation and apoptosis, DU145 cells should be treated with paclitaxel then zoledronic acid. Such a regimen provides the optimal scheme for the sequence-dependent treatment.